Citation Impact
Citing Papers
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
2007
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
2004
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration
2011
Nasopharyngeal carcinoma
2005 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
Imaging beyond the proteome
2012 StandoutNobel
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Testicular Germ-Cell Cancer
1997 Standout
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial
2001
A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
2011 Standout
Adjuvant and Neoadjuvant Therapy for Gastric Cancer
2005
Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist
2014
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial
2004
Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study
2003
Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA
2007
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
Soft Tissue Sarcomas
2004
Validation and updating of predictive logistic regression models: a study on sample size and shrinkage
2004
Internal validation of predictive models
2001 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Osteoblastic cells regulate the haematopoietic stem cell niche
2003 StandoutNature
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
2002
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*
2003
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
2006
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
Dose‐intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first‐line treatment of advanced or metastatic adult soft tissue sarcoma
2008
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function
2004 StandoutNobel
Outpatient Treatment of Neutropenic Fever with Oral Antibiotics and Granulocyte Colony-Stimulating Factor
1999
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
1997
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
3 The Medicinal Chemistry of the Azido Group
1994
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
2002
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
2005
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
2008
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Reporting and Methods in Clinical Prediction Research: A Systematic Review
2012
Worldwide access to treatment for end-stage kidney disease: a systematic review
2015 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
1998
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
1992
Chemistry in living systems
2005 StandoutNobel
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
2011
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes
2007 StandoutNobel
Assessing the Performance of Prediction Models
2009 Standout
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
2009
Predicting Mortality Among Patients Hospitalized for Heart Failure
2003 Standout
Substantial effective sample sizes were required for external validation studies of predictive logistic regression models
2005
Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
2008
Herpes Zoster
2013 Standout
Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy
1998
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials
2005
Tumour stem cells and drug resistance
2005 Standout
In Vitro Development of Primitive and Definitive Erythrocytes from Different Precursors
1996 StandoutScienceNobel
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Statistical aspects of prognostic factor studies in oncology
1994
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy
2005
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma
2004
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
1996 Standout
Decision Curve Analysis: A Discussion
2007
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
1974 StandoutNobel
Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse
1991
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
1973 StandoutNobel
Prognostic Modeling with Logistic Regression Analysis
2001
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Attempts at Identification of Hemopoietic Stem Cell in Mouse
1971
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
VALIDATION OF A PREDICTION MODEL AND ITS PREDICTORS FOR THE HISTOLOGY OF RESIDUAL MASSES IN NONSEMINOMATOUS TESTICULAR CANCER
2001
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Extending the c‐statistic to nominal polytomous outcomes: the Polytomous Discrimination Index
2012
Haematopoietic stem cell content of murine bone marrow, spleen, and blood. Limiting dilution analysis of diffusion chamber cultures
1971
Postchemotherapy Retroperitoneal Surgery Remains Necessary in Patients With Nonseminomatous Testicular Cancer and Minimal Residual Tumor Masses
2003
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Isolation of murine pluripotent hemopoietic stem cells.
1984
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
2002
Purification and Characterization of Mouse Hematopoietic Stem Cells
1988 StandoutScience
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma
2008
Prognosis and prognostic research: application and impact of prognostic models in clinical practice
2009
Works of H.J. Keizer being referenced
Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer
1999
Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections
1994
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study
2002
Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis
1993
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial
1999
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.
1998
Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine
1994
Pathogenesis of malignant ascites: Starling’s law of capillary hemodynamics revisited
2001
A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma
1989
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2002
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients
2003
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
1997
Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.
1996
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria
1996
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2000
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
1995
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM
2000
Residual mass histology in testicular cancer: development and validation of a clinical prediction rule
2001
Feasibility study on daily administration of cis-diamminedichloroplatinum(II) in combination with radiotherapy
1984
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
2000
Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer
1999
Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis.
1999
Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer (ACC)
1999
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor
1997
THE EFFICIENCY OF THE ASSAY FOR HAEMOPIETIC COLONY FORMING CELLS
1970
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group.
1997
Thromboembolic Events During Chemotherapy for Germ Cell Cancer: A Cohort Study and Review of the Literature
2000